Wegovy and Ozempic (semaglutide) associated with reduction in alcohol addiction
GLP‑1 agonist drugs such as Ozempic and Wegovy, originally developed for diabetes and now widely used for weight loss, are increasingly being linked to broader effects like reduced alcohol and other addictions. Commenters weigh their apparent “miracle” benefits—large, sustained weight loss, lower cardiovascular risk, possible addiction relief—against concerns about long‑term safety, loss of muscle and bone mass, weight regain after stopping, high pricing, and the ethics of relying on lifelong medication instead of addressing environmental and behavioral causes of obesity. Many see them as a transformative but imperfect tool, whose societal impact will depend on cost, access, regulation, and how they are combined with lifestyle and psychological support.
Cost, patents, and access
- Manufacturing cost of semaglutide is claimed to be very low (on the order of dollars per month), with high prices attributed to health-system pricing rather than production cost.
- Some expect complex peptide manufacturing to delay cheap generics even after patent expiry; others argue generics will appear quickly given the profit incentive.
Effectiveness, relapse, and lifelong use
- Very strong appetite and weight-loss effects reported; some frame GLP-1 agonists as near-“utopic” or vitamin-like for modern metabolism.
- Major concern: stopping often leads to regaining a large fraction of lost weight within a year; aggregate data suggest ~2/3–70% regain, though some weight tends to stay off.
- Debate over whether these drugs should be seen like lifelong treatments for hypertension/diabetes (just keep taking them) vs a temporary aid that must be paired with durable behavior change.
Side effects and long-term safety
- Reported/feared issues: loss of muscle mass, bone density, tendon/ligament weakness, bowel/GI problems, possible thyroid risk for some GLP-1s.
- Others argue much of the muscle/bone loss is typical of rapid weight loss by any method, and long-term GLP-1 use in diabetics suggests no dramatic undiscovered harms so far.
- Concern about rapid weight regain after discontinuation and its health impact is raised but data are described as incomplete.
Mechanisms, addiction, and behavior
- Thread topic emphasizes reduced alcohol and possibly other addictive behaviors; some see this as transformative for multiple addictions.
- Questions about whether addiction benefits persist after stopping, or simply shift once the drug is removed, remain open/unclear.
- Some worry about personality or motivational changes when “messing with fundamental hormones.”
Lifestyle, ethics, and society
- Strong disagreement over “just eat less / walk more” vs recognition that biological, environmental, and psychosocial factors make sustained weight loss extremely difficult.
- Obesity is increasingly framed by some as an addiction-like, trauma-linked, or neurodevelopmentally influenced condition rather than a moral failing.
- Fears that powerful food/alcohol industries will lobby against widespread GLP-1 use; others note pharma is equally powerful on the opposite side.
- Large potential population-level benefits (fewer cardiac events, diabetes, liver fat, etc.) are cited, leading some to argue governments should subsidize access.